deltatrials
Completed PHASE1 NCT00001018

A Study of Letrazuril in the Treatment of AIDS-Related Diarrhea

Blinded, Placebo-Controlled, Single-Dose Pharmacokinetics and Dose Escalation, Efficacy, and Safety Study of Letrazuril for AIDS-Related Cryptosporidial Diarrhea

Sponsor: Janssen Pharmaceuticals

Conditions Cryptosporidiosis HIV Infections
Interventions Letrazuril
Updated 5 times since 2017 Last updated: Jun 23, 2005

A PHASE1 clinical study on Cryptosporidiosis and HIV Infections, this trial is completed. The trial is conducted by Janssen Pharmaceuticals and has accumulated 5 data snapshots since 2026. Infectious disease trials contribute critical data for public health response and treatment development.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Janssen Pharmaceuticals
  • National Institute of Allergy and Infectious Diseases (NIAID)
Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Los Angeles, United States
  • • New York, United States